Please assess the completion status of the following clinical trial:

Trial Title: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are candidates for routine, uncomplicated cataract surgery.~* Subjects must be willing to wait to undergo cataract surgery on the fellow eye until after the study has been completed.~Exclusion Criteria:~* Subjects who are expected to require treatment with any systemic or ocular (either eye) drugs specified in the protocol during the 18 days following cataract surgery or any systemic or ocular corticosteroids within 14 days prior to cataract surgery.~* Subjects who have known hypersensitivity or contraindication to the study drug(s) or their components.~* Subjects who have a severe/serious ocular condition or history/presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the result(s) of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mapracorat (Type: EXPERIMENTAL): Mapracorat ophthalmic suspension
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle of mapracorat ophthalmic suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).